Key Highlights

  • Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) gained 29.68% after third-quarter Revenue jumped 44% to USD 107.2 million and the 2030 revenue target was raised above USD 1 billion.
  • Vericel Corporation (NASDAQ:VCEL) rose 20.27% after revenue grew 26% to USD 85.4 million and full-year guidance was lifted to USD 344 million to USD 346 million.
  • ADMA Biologics, Inc. (NASDAQ:ADMA) rallied 25.52% as ASCENIV revenue climbed 31% to USD 124.7 million, while total revenue rose only 5% to USD 141.1 million.
  • Arq climbed 30.28% after posting a USD 2.5 million profit, and CareCloud advanced 23.33% after describing its quarter as its most profitable.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS): Higher Guidance and a Larger 2030 Goal

The strongest reaction came at Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), which climbed 29.68% to USD 13.57 in trading on November 5, 2026, according to published market data, after third-quarter results came out the same day. Revenue jumped 44% to USD 107.2 million from USD 74.4 million, driven by Recorlev, a treatment for Cushing's syndrome, which rose 93% to USD 71.5 million. Net Income reached USD 11.3 million versus USD 0.6 million, and adjusted EBITDA was USD 30.8 million. The company lifted 2026 revenue guidance to USD 395 million to USD 405 million and its 2030 outlook to more than USD 1 billion from about USD 750 million. Not every line expanded: Gvoke declined 14% to USD 21.7 million, including a one-time gross-to-net adjustment of about USD 4 million. Recorlev accounts for roughly two-thirds of revenue on simple arithmetic, so concentration is the main risk. Long-term Debt stood at USD 189.7 million against USD 131.1 million of cash, and a 2030 target is an aspiration rather than a contract.

ADMA Biologics, Inc. (NASDAQ:ADMA): Earnings Outpacing Sales Growth

Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) rose 25.52% to USD 13.16 following results released November 4, 2026. Revenue reached USD 141.1 million, up 5%, though ASCENIV, its immune globulin for primary immunodeficiency, increased 31% to USD 124.7 million while the older BIVIGAM line dropped 35% to USD 15.4 million. GAAP net income surged 37% to USD 49.9 million and adjusted EBITDA climbed 32% to USD 77.3 million. The company raised its adjusted net income guidance to at least USD 180 million and its adjusted EBITDA guidance to at least USD 275 million, and reaffirmed revenue of at least USD 530 million. The size of the increase cannot be checked against earlier minimums. A shift in mix toward higher-priced ASCENIV explains why profit outpaced sales. Buybacks of 16.5 million shares so far this year have been partly financed with borrowing, leaving total debt near USD 195.9 million on simple arithmetic. Reliance on one product and a modest 5% sales gain leave room for disappointment, and gains of this size can give back ground.

Vericel Corporation (NASDAQ:VCEL): Gains Across Both Product Lines

The 20.27% advance at Vericel Corporation (NASDAQ:VCEL), to USD 54.70, followed third-quarter results on November 5, 2026. Total net revenue grew 26% to USD 85.4 million from USD 67.5 million. MACI, the cartilage repair therapy, brought in USD 67.4 million, and the company noted its highest quarterly MACI Arthro case count since launch. Burn Care revenue climbed 52% to USD 18.0 million, including USD 3.0 million of procurement revenue from the Biomedical Advanced Research and Development Authority. Net income rose 179% to USD 14.2 million, and adjusted EBITDA Margin widened to 30% from 25%, reflecting the Operating Leverage common to specialty Biologics firms with a largely Fixed Cost base. Full-year revenue guidance was raised to USD 344 million to USD 346 million from USD 330 million to USD 340 million. Cash stood at USD 235.6 million with no debt. The risks are valuation, since published market data implies a multiple near 118 on trailing earnings, and dependence on MACI, which accounts for about four-fifths of revenue. Volume was below average, so the quoted gain may partly reverse.

Arq, Inc. (NASDAQ:ARQ): Better Margins Fueling a Small-Cap Rally

Arq, Inc. (NASDAQ:ARQ) rose 30.28% to USD 2.41 on roughly 29.6 times its usual volume, following third-quarter results released November 4, 2026. Revenue increased to USD 38.2 million from USD 35.1 million, about 8.8% on simple arithmetic, while gross margin widened to 39.7% from 28.8%. Each unit of revenue therefore left more to cover fixed costs, which explains the move to a USD 2.5 million net profit, or USD 0.06 per diluted share. Adjusted EBITDA reached USD 8.8 million compared with USD 5.2 million. Guidance calls for revenue of USD 120 million to USD 125 million and adjusted EBITDA of USD 19 million to USD 20 million, with the lower end of the EBITDA range lifted. The Balance Sheet is less comfortable: cash was USD 19.1 million, of which USD 11.3 million is restricted, against debt of USD 28.2 million. Management has said PFAS treatment orders are not expected before 2027. As a small cap, a limited number of trades can move the price, and quoted moves can reverse.

CareCloud, Inc. (NASDAQ:CCLD): Record Profit Paid for With Borrowing

CareCloud, Inc. (NASDAQ:CCLD) climbed 23.33% to USD 2.22 after third-quarter results on November 5, 2026, ahead of an 8:30 a.m. ET call. Revenue reached USD 33.7 million, up 9%, GAAP net income grew 54% to USD 4.7 million and adjusted EBITDA hit USD 9.9 million, a 29% margin. Chief Executive Stephen Snyder described it as the most profitable quarter in company history, and management reaffirmed 2026 guidance of USD 128 million to USD 132 million in revenue and USD 29 million to USD 31 million in adjusted EBITDA. Nine-month adjusted EBITDA of USD 21.2 million implies about USD 7.8 million to USD 9.8 million in the fourth quarter, simple arithmetic on published figures. The company redeemed its Series B preferred stock on May 15, 2026 using a Credit facility, which eliminated a preferred Dividend but raised loans to USD 37.3 million, while cash was only USD 4.6 million. Shareholders' Equity fell to USD 22.6 million. With a micro-cap float and about 933,000 shares traded, quoted moves can reverse.

Where Things Stand

The evidence suggests these are mostly earned rallies: each company reported higher profit and either raised or reaffirmed guidance, though quality and durability vary. Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) and Vericel paired growth with higher outlooks. ADMA Biologics, Inc. (NASDAQ:ADMA) posted profit growth far ahead of sales. Arq, Inc. (NASDAQ:ARQ) and CareCloud rose from smaller bases, with debt and thin Liquidity as counterweights. After one-session moves of 20% to 30%, expectations are higher, and a quoted intraday gain can partly reverse. Nothing here implies the rise will continue. The next catalysts are fourth-quarter reports, Recorlev prescription trends, MACI delivery against the new range and the debt paydown at CareCloud, Inc. (NASDAQ:CCLD).